A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's Disease: Recommendations of the ISCTM* Working Group
- PMID: 32920630
- DOI: 10.14283/jpad.2020.37
A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's Disease: Recommendations of the ISCTM* Working Group
Conflict of interest statement
COG is an employee of Axsome Therapeutics, Inc. MC and SK are full-time employees of Pfizer Inc. SD is a full-time employee of Avanir Pharmaceuticals, Inc. LE holds chief scientific officer positions at Hassman Reseach Institute and CNS Network. GG is a consultant for Acadia, Alkahest, Allergen, Avanir, Axovant, Bioxcel, GE, Genentech, Lundbeck, Novartis, Otsuka, Roche and Takeda; has received research support from Janssen, Roche and the National Institute of Aging (NIA); has been on safety monitoring committees for EryDel, Merck and Newron; and is on a speaker bureau for Acadia. NH and SL are full-time employees of Lundbeck. HM is co-founder and acting CMO at Exciva GmbH. PR has received support for this work through grants 5R01AG054771 and 5R01AG050515-03 from the National Institute of Aging (NIA) and has received support for other research from Eli Lilly, the Alzheimer’s Association and the NIA. No other disclosures were reported.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical